Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BlackRock Health Sciences Opportunities Portfolio (BME) scores 49/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 5 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.
BlackRock Health Sciences Opportunities Portfolio scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a mixed business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BME's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where BlackRock Health Sciences Opportunities Portfolio scores well and where it falls behind.
BlackRock Health Sciences Opportunities Portfolio runs a net margin of about 99.3%. Revenue has grown at roughly 9.1% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.